High-dose ceftriaxone noninferior to dual therapy for extrag
High-dose ceftriaxone monotherapy is as effective as dual therapy for the treatment of extragenital Neisseria gonorrhoeae among men who have sex with men, study results from Japan showed.

Evidence on efficacy of high-dose ceftriaxone monotherapy for extragenital Neisseria gonorrhoeae (NG) infection is lacking.

A cohort of men who have sex with men (MSM) were tested for NG/Chlamydia trachomatis (CT) every three months, in a single-center observational study in Tokyo, Japan. MSM aged > 19 years diagnosed with extragenital NG infection between 2017 and 2020 were included. A single dose of 1 g ceftriaxone monotherapy was provided, while dual therapy with a single oral dose of 1 g azithromycin or 100 mg doxycycline administered orally twice daily for seven days were given, for those co-infected with CT, according to infected sites.

Efficacy of these treatments was calculated by the number of NG-negative subjects at test-of-cure divided by the number of subjects treated. Fisher’s exact tests were used to compare the efficacy between the two groups.

-- Of 320 cases diagnosed with extragenital NG, 208 were treated with monotherapy and 112 were treated with dual therapy.

-- The efficacy against total, pharyngeal, and rectal infections was 98.1%, 97.8%, and 98.6%, respectively, in the monotherapy group, while the corresponding efficacy in the dual therapy was 95.5%, 96.1% and 95.1%, respectively.

-- No significant difference in the corresponding efficacy was observed between the two groups.

Conclusively, high-dose ceftriaxone monotherapy is as effective as dual therapy for extragenital NG among MSM.

Source: https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciab455/6277038?redirectedFrom=fulltext